New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:58 EDTSTI, TCP, NVS, FDO, BMRN, GPRE, LPL, SRE, LB, DG, ARCO, MTU, OXM, PFG, SJM, COFOn The Fly: Analyst Upgrade Summary
Arcos Dorados (ARCO) upgraded to Buy from Underperform at BofA/Merrill... BioMarin (BMRN) upgraded to Outperform from Neutral at Credit Suisse... Capital One (COF) upgraded to Buy from Neutral at Nomura... Dollar General (DG) upgraded to Buy from Hold at Jefferies... Family Dollar (FDO) upgraded to Buy from Hold at Jefferies... J.M. Smucker (SJM) upgraded to Market Perform from Underperform at Wells Fargo... L Brands (LB) upgraded to Perform from Underperform at Oppenheimer... Novartis (NVS) upgraded to Equalweight from Underweight at Barclays... Principal Financial (PFG) upgraded to Equal Weight from Underweight at Morgan Stanley... Sempra Energy (SRE) upgraded to Buy from Neutral at ISI Group... TC PipeLines (TCP) upgraded to Equal Weight from Underweight at Barclays... Oxford Industries (OXM) upgraded to Buy from Neutral at Sidoti... LG Display (LPL) upgraded to Outperform from Neutral at Macquarie... SunTrust (STI) upgraded to Outperform from Market Perform at Keefe Bruyette... Mitsubishi UFJ (MTU) upgraded to Buy from Neutral at BofA/Merrill...Green Plains (GPRE) upgraded to Overweight from Equal Weight at Stephens.
News For ARCO;BMRN;COF;DG;FDO;SJM;LB;NVS;PFG;SRE;TCP;OXM;LPL;STI;MTU;GPRE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 19, 2015
16:31 EDTLBL Brands sees Q3 EPS 40c-45c, consensus 48c
Subscribe for More Information
16:30 EDTLBL Brands reports Q2 EPS 68c, consensus 68c
Subscribe for More Information
16:06 EDTBMRNBioMarin receives rare pediatric disease designation from FDA for drisapersen
Subscribe for More Information
14:48 EDTLBNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include L Brands (LB), consensus 68c... NetApp (NTAP), consensus 23c... Synopsys (SNPS), consensus 59c... Popeyes Louisiana Kitchen (PLKI), consensus 44c... Semtech (SMTC), consensus 24c.
13:57 EDTLBL Brands technical notes before earnings
Subscribe for More Information
10:00 EDTSJMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:17 EDTBMRN'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTBMRNFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
07:22 EDTLBL Brands August volatility elevated into Q2 and outlook
L Brands August call option implied volatility is at 36, September is at 26, November is at 24; compared to its 52-week range of 18 to 31 , suggesting large near term price movement into the expected release of Q2 results on August 20.
06:29 EDTSJMJ.M. Smucker upgraded to Outperform on sales growth progress at Credit Suisse
Credit Suisse upgraded J.M. Smucker to Outperform and increased its price target to $126 from $112. The firm said the latest Nielsen data indicates sales growth has turned with notable progress in coffee and pet food. Additionally, Credit Suisse believes management is about to introduce a more aggressive cost savings target for the Big Heart integration and expects shares to narrow the valuation gap versus peers as revenue growth and market share improves.
06:05 EDTPFGPrincipal Financial appoints Daniel J. Houston as CEO
Subscribe for More Information
August 18, 2015
10:00 EDTLBOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abercrombie & Fitch (ANF) initiated with an Underperform at Wolfe Research... Abiomed (ABMD) initiated with a Buy at CRT Capital... Aeropostale (ARO) initiated with a Peer Perform at Wolfe Research... American Eagle (AEO) initiated with an Outperform, Top Pick at Wolfe Research... American Electric (AEP) initiated with a Buy at Mizuho... Benefitfocus (BNFT) initiated with an Overweight at First Analysis... Blue Buffalo Pet Products (BUFF) initiated with an Equal Weight at Morgan Stanley... Capitala Finance (CPTA) initiated with an Equal Weight at Stephens... Chico's (CHS) initiated with a Peer Perform at Wolfe Research... Children's Place (PLCE) initiated with an Outperform at Wolfe Research... Chimerix (CMRX) initiated with an Outperform at FBR Capital... Ciena (CIEN) initiated with a Market Perform at Northland... Crane (CR) initiated with an Outperform at William Blair... Entergy (ETR) initiated with a Neutral at Mizuho... Express (EXPR) initiated with an Outperform, Top Pick at Wolfe Research... Finisar (FNSR) initiated with a Market Perform at Northland... Francesca's (FRAN) initiated with a Peer Perform at Wolfe Research... Gap (GPS) initiated with an Underperform at Wolfe Research... Infinera (INFN) initiated with an Outperform at Northland... International Game (IGT) initiated with a Buy at Union Gaming... Juno Therapeutics (JUNO) initiated with an Outperform at FBR Capital... L Brands (LB) initiated with a Peer Perform at Wolfe Research... Luca Technologies (LUCA) initiated with an Outperform at Northland... Lumentum (LITE) initiated with an Outperform at Northland... M/A-COM (MTSI) reinstated with a Buy at Jefferies... MRV Communications (MRVC) initiated with an Outperform at Northland... Michael Kors (KORS) initiated with a Peer Perform at Wolfe Research... NN, Inc. (NNBR) initiated with a Buy at Stifel... NeoPhotonics (NPTN) initiated with an Outperform at Northland... Oclaro (OCLR) initiated with an Outperform at Northland... Scientific Games (SGMS) initiated with a Buy at Sterne Agee CRT... SolarCity (SCTY) initiated with a Neutral at UBS... Summit Materials (SUM) initiated with a Neutral at Citi... Tech Data (TECD) initiated with an Underperform at BofA/Merrill... Urban Outfitters (URBN) initiated with a Peer Perform at Wolfe Research... Zumiez (ZUMZ) initiated with an Underperform at Wolfe Research... lululemon (LULU) initiated with a Peer Perform at Wolfe Research.
10:00 EDTPFGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:19 EDTNVSPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
05:37 EDTPFGPrincipal Financial downgraded to Market Perform from Outperform at Keefe Bruyette
Subscribe for More Information
August 17, 2015
17:07 EDTLBL Brands initiated with a Peer Perform at Wolfe Research
Subscribe for More Information
13:30 EDTNVSOn The Fly: Top stock stories at midday
Stocks began the session deep in negative territory after a disappointing Empire Manufacturing report. The data got the market off to a weak start as optimism over last week's finish began to fade. The averages continued to drift in a narrow range for the opening hour before reversing and capturing the opening losses. Each of the major equity indices is now back in positive territory sporting slight gains across the board. ECONOMIC EVENTS: In the U.S., the Empire State manufacturing index plunged to -14.92 in August after rebounding to 3.86 in July from June's -1.98. The consensus estimate was 4.75, and the surprising drop puts the index at its lowest point since April 2009. The employment component slid to 1.82, while new orders crashed to -15.70. Meanwhile, the U.S. NAHB homebuilder sentiment index rose to 61 in August from 60 in June and and is the highest since November 2005. The single family sales index edged up to 66 versus a revised 65 last month, while the index of prospective buyer traffic improved to 45 versus 43 previously. In Europe, various Eurozone parliaments prepare to vote on Greece's new EUR86B bailout plan this week. COMPANY NEWS: Liberty Interactive (QVCA) announced this morning an agreement to acquire zulily (ZU) for $18.75 per share in a deal valuing the online shopping site at $2.4B, driving zulily shares up more than 47% in intraday trading. The acquisition will be attributed to Liberty's QVC Group tracking stock, though QVC and zulily will be operated as separate consumer facing brands. On a conference call discussing the acquisition, Liberty Interactive executives noted that the "highly efficient" deal will allow Liberty to reach a younger base. MAJOR MOVERS: Among the notable gainers AVEO Oncology (AVEO), which rose roughly 50% after announcing a license agreement with Novartis (NVS) for the development and commercialization of AVEO's AV-380 drug and related antibodies. Also higher was Kite Pharma (KITE), which advanced roughly 5.4% after clarifying that an earlier patient death in its Phase 1/2 KTE-C19 trial for non-Hodgkin's lymphoma was unrelated to Kite's therapy. Additionally, shares of Target (TGT) have gained roughly 10c despite lingering in negative territory early Monday after the company promoted CFO John Mulligan to the newly created role of EVP and COO and appointed Cathy Smith as EVP and CFO. Prior to joining Target, Smith served as EVP and CFO at St. Louis-based Express Scripts (ESRX). Among the noteworthy losers was KKR (KKR), which lost roughly 2.4% after Samson Resources announced a restructuring agreement late Friday, adding that it expects to file for bankruptcy within 30 days. Also lower was Estee Lauder (EL), which declined nearly 6.5% after its quarterly guidance missed analysts' estimates. INDEXES: Near midday, The Dow was up 65.11, or 0.37%, to 17,542.51, the Nasdaq gained 34.73, or 0.69%, to 5,082.96, and the S&P 500 advanced 8.80, or 0.42%, to 2,101.03.
09:01 EDTSRESempra Energy management to meet with JPMorgan
Meetings to be held in Dallas on August 19 and in Denver/Kansas City on August 20 hosted by JPMorgan.
06:11 EDTCOFCapital One reports July net charge-offs 3.05% vs. 3.23% last month
Reports July 30+ day performing delinquency rate 2.97% vs. 2.84% last month.
06:01 EDTNVSAVEO Oncology announces license agreement with Novartis
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use